ANVS / INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficie more_horizontal

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of th more_horizontal

EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023. more_horizontal

Investor confusion surrounding Annovis's interim analysis of its Phase 3 Parkinson's (PD) study highlights the need, in my view, for improved PR proce more_horizontal

Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy more_horizontal

Lead asset buntanetap represents a differentiated, potentially disease-modifying mechanism of action in neurodegenerative diseases. Interim Phase 3 Pa more_horizontal

Annovis Bio, Inc. (ANVS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound sto more_horizontal

Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year. more_horizontal